Scholarlink

Background <p>Immunotherapy has established itself as the standard treatment for advanced renal cell carcinoma (RCC), being used as a primary option alongside tyrosine kinase inhibitors (TKIs) as well as in later lines of therapy.</p> Case presentation <p>We present the case of a 67-year-old man from Latin America who experienced anemia and fatigue. A physical examination indicated tenderness in the left flank. An abdominal CT scan revealed a mass measuring 60 × 44&#xa0;mm in the left kidney, while a chest CT displayed multiple nodules in both lungs. The clinical assessment led to a diagnosis of stage IV renal cell carcinoma (T1bN0M1). The patient had cytoreductive nephrectomy performed, followed by 25&#xa0;months of sunitinib treatment. After the disease progressed, he was treated with everolimus, an mTOR inhibitor, but showed limited response. He then started third-line therapy with nivolumab, an immune checkpoint inhibitor (ICI), achieving a complete response after 48&#xa0;months of treatment. He remains free of disease to this day.</p> Conclusions <p>We present a review of existing literature regarding the application of immunotherapy in this context, focusing on the timing and length of treatment for patients who have shown a clinical response, along with the possible advantages of maintaining immunotherapy treatment even after disease progression. Further research is essential to establish the most effective treatment duration and to pinpoint predictive biomarkers and criteria for selecting patients for tailored therapeutic approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term survival with nivolumab in a patient with renal cell carcinoma: a case report and review of the literature

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Patricia Rioja,
  • Guillermo Valencia,
  • Zaida Morante,
  • Fernando Valencia,
  • Silvia Neciosup,
  • Tatiana Vidaurre

摘要

Background

Immunotherapy has established itself as the standard treatment for advanced renal cell carcinoma (RCC), being used as a primary option alongside tyrosine kinase inhibitors (TKIs) as well as in later lines of therapy.

Case presentation

We present the case of a 67-year-old man from Latin America who experienced anemia and fatigue. A physical examination indicated tenderness in the left flank. An abdominal CT scan revealed a mass measuring 60 × 44 mm in the left kidney, while a chest CT displayed multiple nodules in both lungs. The clinical assessment led to a diagnosis of stage IV renal cell carcinoma (T1bN0M1). The patient had cytoreductive nephrectomy performed, followed by 25 months of sunitinib treatment. After the disease progressed, he was treated with everolimus, an mTOR inhibitor, but showed limited response. He then started third-line therapy with nivolumab, an immune checkpoint inhibitor (ICI), achieving a complete response after 48 months of treatment. He remains free of disease to this day.

Conclusions

We present a review of existing literature regarding the application of immunotherapy in this context, focusing on the timing and length of treatment for patients who have shown a clinical response, along with the possible advantages of maintaining immunotherapy treatment even after disease progression. Further research is essential to establish the most effective treatment duration and to pinpoint predictive biomarkers and criteria for selecting patients for tailored therapeutic approaches.